Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.37 |
| ▸ | ARG1 | P05089 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | OGA | O60502 | 1/20 | 0.32 |
| ▸ | PEPD | P12955 | 1/20 | 0.32 |
| ▸ | ARG2 | P78540 | 2/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4314936 | 0.83 | METAP2 (0.35) | CTSK | |
| SCHEMBL4314933 | 0.83 | METAP2 (0.35) | CTSK | |
| SCHEMBL4314924 | 0.83 | METAP2 (0.35) | CTSK | |
| SCHEMBL4318923 | 0.79 | CACNA1B (0.43) | CACNA1BDPP4ARG1CTSKPEPD | |
| SCHEMBL4310039 | 0.76 | CTSK (0.36) | CACNA1BDPP4CTSK | |
| SCHEMBL5948848 | 0.74 | CACNA1B (0.36) | CACNA1BDPP4ARG1CTSKPEPD | |
| SCHEMBL4318521 | 0.73 | POLB (0.47) | CACNA1BDPP4CTSKPEPD | |
| SCHEMBL4327583 | 0.73 | POLB (0.47) | CACNA1BDPP4CTSKPEPD | |
| SCHEMBL4327587 | 0.73 | POLB (0.47) | CACNA1BDPP4CTSKPEPD | |
| SCHEMBL4318518 | 0.73 | POLB (0.47) | CACNA1BDPP4CTSKPEPD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | claimed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | claimed |
| US-7563784-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2009-07-21 | — | — | US | disclosed |
| US-20060194787-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-08-31 | — | — | US | disclosed |
| US-7071184-B2 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-20040044201-A1 | Protease inhibitors | GLAXOSMITHKLINE LLC | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194787-A1 | Protease inhibitors | CTSK, CTSL, CTSZ | CACNA1B 4408/4885DPP4 80/4885ARG1 1045/4885 |
| US-20040044201-A1 | Protease inhibitors | CTSK, CTSE, CTSZ | CACNA1B 4272/4885DPP4 40/4885ARG1 989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.